Study on hnRNPA1 Pathobiology in ALS
hnRNPA1在ALS中的病理学研究
基本信息
- 批准号:10188709
- 负责人:
- 金额:$ 31.79万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2020
- 资助国家:美国
- 起止时间:2020-06-11 至 2022-02-28
- 项目状态:已结题
- 来源:
- 关键词:ALS patientsAffinityAllelesAminobutyric AcidsAmyotrophic Lateral SclerosisAnimal ModelAnimalsBindingBiological AssayBiological MarkersBiological ModelsBiological ProcessCell physiologyClinicalDiseaseDisease ProgressionElectron TransportEndoplasmic ReticulumExhibitsFamilyGenesGeneticGenetic EngineeringGenomicsImpairmentKnock-inKnock-outLinkLongevityMeasuresMetabolismMitochondriaMitochondrial ProteinsModelingMolecularMonitorMorphologyMutateMutationNerve DegenerationNucleosidesNucleotidesPathogenesisPathogenicityPathway interactionsPatternPhenotypePhysiologicalPlayPoint MutationProtein ImportProteinsRNARNA ProcessingRattusResearchRibonucleoproteinsRoleSignal PathwayTherapeutic EffectTransgenic AnimalsTransgenic OrganismsUntranslated Regionsautosomal dominant traitdisease-causing mutationeggfunctional lossgain of functiongamma-Aminobutyric Acidimprovedknock-downknockout animalmitochondrial dysfunctionmutantneuropathologyneurotoxicitynoveloverexpressionpreservationprotein TDP-43public health relevancesuperoxide dismutase 1
项目摘要
DESCRIPTION (provided by applicant): Mutations in hnRNPA1 are recently found in multiple families with amyotrophic lateral sclerosis (ALS). HnRNPA1 is known to regulate RNA processing and to interact with proteins related to varying cellular functions, but how hnRNPA1 mutation causes disease is not known. A critical step towards understanding hnRNPA1 pathogenesis is determining the effect of pathogenic mutation on hnRNPA1 function at both systematic and molecular levels. HnRNPA1, TDP-43 and FUS belong to ribonucleoprotein family and their mutations are all associated with ALS. The three ribonucleoproteins exhibit similarity in disease features: 1) the disease shows an autosomal dominant trait; 2) proteinopathy and mitochondrial impairment is prominent in the disease; and 3) both wildtype and mutant forms cause diseases when overexpressed in animal models. Even seven years after the discovery of TDP-43 mutation in ALS, how TDP-43 mutation causes the disease remains elusive. Our preliminary studies show that both deficiency and excess in hnRNPA1 expression causes neurotoxicity respectively in hnRNPA1 knockdown and transgenic rats, suggesting that hnRNPA1 must be tightly regulated to maintain its normal function. To unravel the effect of pathogenic mutation on hnRNPA1, we created hnRNPA1 knockin rats in which a single pathogenic mutation is introduced. The knockin rats differ from their wildtype littermates in a single nucleotide examined. Any phenotypes detected in the knockin rats must result from the pathogenic mutation. With unprecedented rat models, we will examine how pathogenic mutation impacts hnRNPA1 function at both the systematic and molecular levels, revealing the mechanism by which hnRNPA1 mutation causes neurodegeneration in ALS.
描述(由适用提供):HNRNPA1中的突变最近在肌萎缩性侧索硬化症(ALS)的多个家族中发现。已知HNRNPA1可以调节RNA处理并与与细胞功能不同的蛋白质相互作用,但是HNRNPA1突变如何引起疾病。了解HNRNPA1发病机理的关键步骤是确定致病性突变对系统和分子水平上HNRNPA1功能的影响。 HNRNPA1,TDP-43和FUS属于核糖核蛋白家族及其突变都与ALS相关。三种核糖核蛋白在疾病特征中暴露了相似性:1)疾病表现出常染色体显性特征; 2)蛋白质病和线粒体损伤在疾病中很明显; 3)在动物模型中过表达时,野生型和突变形式会引起疾病。甚至在ALS中发现TDP-43突变的七年后,TDP-43突变如何引起该疾病仍然难以捉摸。我们的初步研究表明,HNRNPA1敲低和转基因大鼠的缺乏症和超过HNRNPA1表达都会引起神经毒性,这表明必须严格调节HNRNPA1以维持其正常功能。为了揭示致病突变对HNRNPA1的影响,我们创建了HNRNPA1敲击蛋白大鼠,其中引入了单个致病性突变。在检查的单个核丁物中,敲击大鼠与其野生型同窝窝不同。在敲击大鼠中检测到的任何表型都必须由致病性突变引起。使用前所未有的大鼠模型,我们将研究致病突变如何在系统和分子水平上影响HNRNPA1功能,从而揭示HNRNPA1突变导致ALS神经变性的机制。
项目成果
期刊论文数量(3)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Increased Ubqln2 expression causes neuron death in transgenic rats.
- DOI:10.1111/jnc.13748
- 发表时间:2016-10
- 期刊:
- 影响因子:4.7
- 作者:Huang B;Wu Q;Zhou H;Huang C;Xia XG
- 通讯作者:Xia XG
Detergent-insoluble inclusion constitutes the first pathology in PFN1 transgenic rats.
- DOI:10.1111/jnc.15139
- 发表时间:2021-05
- 期刊:
- 影响因子:4.7
- 作者:Yuan G;Cui S;Chen X;Song H;Huang C;Tong J;Yuan Z;Yu L;Xiong X;Zhao J;Huang B;Wu Q;Zhou Y;Chen G;Zhou H;Xia XG
- 通讯作者:Xia XG
Increase in hnRNPA1 Expression Suffices to Kill Motor Neurons in Transgenic Rats.
- DOI:10.3390/ijms242216214
- 发表时间:2023-11-11
- 期刊:
- 影响因子:5.6
- 作者:
- 通讯作者:
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
xugang xia其他文献
xugang xia的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('xugang xia', 18)}}的其他基金
TMEM230 and Neurodegeneration in Parkinson's Disease
TMEM230 与帕金森病的神经退行性变
- 批准号:
10705592 - 财政年份:2020
- 资助金额:
$ 31.79万 - 项目类别:
TMEM230 and Neurodegeneration in Parkinson's Disease
TMEM230 与帕金森病的神经退行性变
- 批准号:
9974760 - 财政年份:2020
- 资助金额:
$ 31.79万 - 项目类别:
TMEM230 and Neurodegeneration in Parkinson's Disease
TMEM230 与帕金森病的神经退行性变
- 批准号:
10268170 - 财政年份:2020
- 资助金额:
$ 31.79万 - 项目类别:
TMEM230 and Neurodegeneration in Parkinson's Disease
TMEM230 与帕金森病的神经退行性变
- 批准号:
10459555 - 财政年份:2020
- 资助金额:
$ 31.79万 - 项目类别:
Study on PFN1 Pathobiology Using Rat Models
利用大鼠模型进行 PFN1 病理学研究
- 批准号:
10376166 - 财政年份:2019
- 资助金额:
$ 31.79万 - 项目类别:
Study on PFN1 Pathobiology Using Rat Models
利用大鼠模型进行 PFN1 病理学研究
- 批准号:
9912205 - 财政年份:2019
- 资助金额:
$ 31.79万 - 项目类别:
Study on PFN1 Pathobiology Using Rat Models
利用大鼠模型进行 PFN1 病理学研究
- 批准号:
10189826 - 财政年份:2019
- 资助金额:
$ 31.79万 - 项目类别:
Study on PFN1 Pathobiology Using Rat Models
利用大鼠模型进行 PFN1 病理学研究
- 批准号:
10604337 - 财政年份:2019
- 资助金额:
$ 31.79万 - 项目类别:
相似国自然基金
基于计算生物学技术小分子农兽药残留物驼源单域抗体虚拟筛选与亲和力成熟 -以内蒙古阿拉善双峰驼为例
- 批准号:32360190
- 批准年份:2023
- 资助金额:34 万元
- 项目类别:地区科学基金项目
基于胞内蛋白亲和力标记策略进行新型抗类风湿性关节炎的选择性OGG1小分子抑制剂的发现
- 批准号:82304698
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
基于多尺度表征和跨模态语义匹配的药物-靶标结合亲和力预测方法研究
- 批准号:62302456
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
框架核酸多价人工抗体增强靶细胞亲和力用于耐药性肿瘤治疗
- 批准号:32301185
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
抗原非特异性B细胞进入生发中心并实现亲和力成熟的潜力与调控机制
- 批准号:32370941
- 批准年份:2023
- 资助金额:50 万元
- 项目类别:面上项目
相似海外基金
Discovery and Roles of In Situ Islet Neoantigens in Human Type 1 Diabetes
原位胰岛新抗原在人类 1 型糖尿病中的发现及其作用
- 批准号:
10589578 - 财政年份:2023
- 资助金额:
$ 31.79万 - 项目类别:
The role of SH2B3 in regulating CD8 T cells in Type 1 Diabetes
SH2B3 在 1 型糖尿病中调节 CD8 T 细胞的作用
- 批准号:
10574346 - 财政年份:2023
- 资助金额:
$ 31.79万 - 项目类别:
Activity-Dependent Regulation of CaMKII and Synaptic Plasticity
CaMKII 和突触可塑性的活动依赖性调节
- 批准号:
10817516 - 财政年份:2023
- 资助金额:
$ 31.79万 - 项目类别:
Alpha-Synuclein-Specific T cells in Parkinson's Disease Pathogenesis
帕金森病发病机制中的α-突触核蛋白特异性 T 细胞
- 批准号:
10752172 - 财政年份:2023
- 资助金额:
$ 31.79万 - 项目类别:
Targeting DNA Mismatches for Auger Electron Radiotherapy
针对 DNA 错配进行俄歇电子放射治疗
- 批准号:
10751210 - 财政年份:2023
- 资助金额:
$ 31.79万 - 项目类别: